Background: Plasma amyloid ␤-peptide (A␤) 40 and A␤42 levels are increased in persons with mutations causing early-onset familial Alzheimer's disease (AD). Plasma A␤42 levels were also used to link microsatellite genetic markers to a putative AD genetic locus on chromosome 10 and were observed in patients with incipient sporadic AD. Methods: The authors measured plasma A␤40 and A␤42 levels using a sandwich ELISA after the initial examination of 530 individuals participating in an epidemiologic study of aging and dementia. Participants were examined at 18-month intervals, and plasma A␤40 and A␤42 levels were repeated in 307 subjects 3 years after baseline. Results: Compared with individuals who never developed AD, patients with AD at baseline and those who developed AD during the follow-up had significantly higher A␤42, but not A␤40, plasma levels. The risk of AD in the highest quartile of plasma A␤42 was increased by more than twofold over that in the lowest quartile. The highest plasma A␤42 levels were observed in patients with AD who died during the follow-up. Plasma A␤42, but not A␤40, levels decreased over time in patients with newly acquired AD. Conclusions: Plasma A␤40 and A␤42 increase with age and are strongly correlated with each other. Plasma A␤40 and A␤42 levels are elevated in some patients before and during the early stages of AD but decline thereafter. High plasma A␤42 levels may also be associated with mortality in patients with AD.
Methods. Study population. Plasma A␤40 and A␤42 and clinical data were obtained from 530 individuals randomly selected from 2,126 Medicare recipients, 65 years and older, residing in northern Manhattan in New York City and participating in a study of aging and dementia. The sampling procedures for the parent study have been described elsewhere. 13 Participants underwent an in-person structured interview of health, a physical and neurologic examination, and a neuropsychological battery at the time of study entry, which was repeated at approximately 18month intervals. Only individuals who completed at least one follow-up were included in the analyses. The Columbia University Institutional Review Board reviewed and approved this project. All individuals provided written informed consent.
Clinical assessments. Physicians completed standardized medical and neurologic histories and examinations. With use of a standard protocol, standing body weight to the nearest 0.1 kg with a balance scale (Scale-Tronix, Wheaton, IL) and height without shoes to nearest 0.5 cm were measured using a stadiometer (GNP, Geneva, Switzerland) to calculate body mass index (BMI ϭ weight/height 2 ).
The neuropsychological test battery, previously validated for this geographic area, 14, 15 was given in either Spanish or English. The battery consisted of the orientation subtest from the modified Mini-Mental State Examination, 16 the Boston Naming Test, 17 the Controlled Word Association Test, 18 category naming, the Complex Ideational Material and Phrase Repetition Subtests of the Boston Diagnostic Aphasia Evaluation, 19 the Abstract Reasoning and Similarities Subtests from the Wechsler Adult Intelligence Scale-Revised, 20 the nonverbal Identities and Oddities Subtest of the Mattis Dementia Rating Scale, 21 the Rosen Drawing Test, 22 the matching version and the multiple-choice version of the Benton Visual Retention Test, 23 and the Selective Reminding Test. 24 After each clinical assessment, a group of physicians and neuropsychologists reviewed the data and reached a consensus regarding the presence or absence of dementia 25 using published criteria for probable and possible AD. 26 Severity of AD was rated using the Clinical Dementia Rating Scale (CDR). 27 The consensus group was shielded from the plasma A␤ levels.
Ethnic group. At baseline, ethnic group was documented by self-report using the format of the 1990 US Census. 28 All individuals were first asked to indicate their racial group and then whether or not they were of "Hispanic origin."
Plasma lipids. Fasting plasma total cholesterol and triglyceride levels had also been determined from plasma ascertained at baseline using standard enzymatic techniques. High-density lipoprotein (HDL) cholesterol was determined after precipitation of ApoB-containing lipoproteins with phosphotungstic acid. Lowdensity lipoprotein cholesterol levels were calculated using the formula of Friedewald et al. 29 This was done to examine the putative relation between alterations in cholesterol and A␤ levels in AD. 30 APOE genotype. Genotypes were obtained by amplification of genomic DNA with PCR subjected to CfoI restriction analysis using APOE primers and conditions similar to those described by Hixson and Vernier 31 and modified by Maestre et al. 32 Plasma A␤40 and A␤42. Plasma obtained at baseline and follow-up was stored within 2 hours after collection at Ϫ70°C. A␤40 and A␤42 levels were measured using a combination of monoclonal antibody 6E10 (specific to an epitope present on 1 to 16 amino acid residues of A␤) and rabbit antibodies specific for A␤40 (R162) and A␤42 (R165) in a double-antibody sandwich ELISA. 33, 34 The detection limit for this assay was 5 pg/mL for A␤40 and 10 pg/mL for A␤42. Previously, we had established that the test-retest reliability of the measurement of plasma A␤40 and A␤42 was excellent (Cronbach's ␣ coefficient ϭ 0.91). 6 Data analysis. Continuous measures were compared across groups using Student's t-test, and categorical variables were compared using the 2 test. We subtracted the value of the plasma A␤ levels at baseline from that acquired 3 years later to estimate the change in levels over time. The change was compared using analysis of variance. Correlations between variables were completed using Pearson's correlation coefficient. Log transformation was used for continuous variables that appeared skewed. Univariate regression models were used to determine the relation between AD and plasma A␤ levels, and multivariate regression models were used to adjust for potential confounders. Finally, we used Cox regression to examine the rate ratio for AD associated with plasma A␤42 levels divided into quartiles, in which the lowest quartile was used as the reference. For these analyses, we used duration of follow-up from the baseline measurement of plasma A␤ levels as the time-to-event variable. In subsequent analyses, we adjusted for age, education, APOE genotype, and BMI. All analyses were conducted using SPSS for Windows (version 10.1.3; Chicago, IL).
Results.
At the baseline assessment, there were 79 (14.9%) patients with clinically diagnosed AD (CDR Ն 1.0) among the 530 individuals in the study. The remaining 451 individuals were free of dementia (400 were CDR ϭ 0 and 51 CDR ϭ 0.5). Over the subsequent 5 years, 65 (16.3%) of the 400 without dementia and 21 (41.2%) of those with mild impairment (CDR ϭ 0.5) developed AD (CDR ϭ 1).
Compared with those who remained healthy, there were more African Americans and Hispanics than whites and more women than men with AD at baseline (table 1) . Patients with AD were also older, less well educated, and more likely to have an APOE-⑀4 allele than those without dementia. Over the follow-up period, more African Americans and Hispanics than whites and more women than men developed AD (see table 1 ). Individuals who developed AD were more likely to be older, less well educated, and more likely to have an APOE-⑀4 allele than those who remained free of dementia. BMI was lower among the patients with AD at baseline than among newly diagnosed patients with AD or control subjects (see table 1 ). Plasma A␤40 and A␤42 levels were correlated (r ϭ 0.22, p ϭ 0.001), and both increased with age (A␤40 r ϭ 0.23, p Ͻ 0.001; A␤42 r ϭ 0.15, p Ͻ 0.001). A␤40, but not A␤42, levels were inversely related to serum cholesterol and HDL levels (r ϭ Ϫ0.12, p ϭ 0.005, for both). A␤42, but not A␤40, level was inversely related to BMI (r ϭ Ϫ0.1, p ϭ 0.05). Neither A␤40 nor A␤42 levels differed by the presence or absence of an APOE-⑀4 allele.
The initial A␤40 and A␤42 levels differed significantly in those individuals with AD at baseline compared with those without dementia (see table 1 ). More importantly, A␤40 and A␤42 levels were significantly higher in those who subsequently developed AD over the follow-up period (see table 1 ). The baseline A␤40 levels, but not the A␤42 levels, differed between those with CDR ϭ 0 and those with CDR ϭ 0.5 (A␤40 131. 5 Because the distributions of A␤40 and A␤42 levels were skewed, the comparison was repeated using log transformations of A␤40 and A␤42 levels, and all of the associations with newly acquired AD described above remained significant. However, with multivariate analysis of covariance adjusting for age, BMI, and A␤40 level, only A␤42 levels remained significantly different when comparing those who never developed AD with those who developed AD over the follow-up period. In contrast, there were no significant differences in the A␤40 level across the groups in the adjusted analysis. We also found no differences in the plasma A␤40 and A␤42 levels by disease severity using either the first or the last CDR rating. However, only two individuals had CDR ratings that exceeded 2, which reflects the fact that most patients had only mild disease.
Compared with the lowest quartile of plasma A␤42 level at baseline, the unadjusted rate ratio for AD was significantly increased for each successive quartile after the second quartile (table 2) . This association did not change in a multivariate Cox regression model that included A␤40 level, age, BMI, education, and APOE-⑀4. The figure shows the cumulative proportion of affected individuals within each quartile of plasma A␤42. Only the upper two quartiles differed significantly from the lowest quartile, though the risk did increase for each quartile.
The baseline A␤42 plasma level was also consistently and significantly higher among those individuals who developed AD at any time point during the follow-up than among those who never developed AD after 5 years of follow-up (mean A␤42 levels for controls over the entire period 58.8 pg/mL, AD after 2 years of follow-up 77.1 pg/ mL, AD after 4.1 years of follow-up 74.5 pg/mL; F ϭ 6.04, p ϭ 0.003). Thus, the average plasma A␤42 levels were consistently elevated among those who subsequently developed AD compared with those who remained dementia-free.
We were able to obtain repeat blood samples in only 307 (58%) of the 530 individuals. This was due in part to mortality among 157 (29.6%) of the participants. Nonetheless, the correlation between the initial and subsequent plasma A␤40 and A␤42 levels was high (0.979 and 0.963, respectively). The change in overall mean A␤40 levels differed slightly, but significantly, increasing over time (2.44 pg/ mL; 95% CI 0.9 to 3.9). There was no significant change in A␤42 level over time (Ϫ0.009 pg/mL; 95% CI Ϫ0.83 to 0.82), but in comparison there were significant differences in plasma A␤42 levels among the different groups over time. Among controls that remained dementia-free, the average difference over the 3 years was 0.25 pg/mL, for prevalent AD the difference was Ϫ0.75 pg/mL, whereas the difference among patients with incident AD was Ϫ3.02 pg/mL (F ϭ 4.2, p ϭ 0.02). This difference was significant. Thus, the average decline in plasma A␤42 levels was 1.006 pg/mL/year in patients with newly acquired AD.
We found that baseline plasma A␤40 and A␤42 levels were significantly higher among those who died before the final assessment (table 3) . Specifically, those individuals with AD who subsequently died had higher baseline A␤42 levels than those individuals without AD, those with AD at baseline, and patients who developed AD and survived. The analysis was repeated using multivariate analysis of covariance adjusting for age, BMI, and baseline plasma A␤40 level, and the difference remained significant. Plasma A␤40 levels did not differ significantly in those who survived with or without AD and those who did not in the multivariate analysis. The unadjusted analysis was repeated using log transformation of the values for plasma A␤40 or the A␤42 levels, and the differences remained statistically significant.
Discussion. Compared with elderly without AD, patients with AD and individuals who developed AD over the follow-up period had higher plasma A␤40 and A␤42 levels at the beginning of the study. Plasma A␤40 and A␤42 levels were also higher in patients with AD at baseline compared with controls, though the differences were smaller. With use of the lowest quartile as the reference group, individuals in the upper two quartiles of plasma A␤42 were at twice the risk of developing AD over the follow-up period. As a group, plasma levels of A␤40 and A␤42 drawn 3 years apart did not change significantly, but there was a significant decline in plasma A␤42 levels in patients with newly acquired AD compared with those with prevalent AD or with controls. Over the study period, both plasma A␤40 and A␤42 levels were higher among those participants who died during the follow-up period than among those who survived. However, the multivariate analysis showed that baseline A␤42 levels were higher in patients with recent onset of AD who died compared with those who survived with or without AD. This work extends our previous study, pointing out that differences in plasma level are related to age, BMI, and duration of time after the diagnosis. It also shows that the risk of AD may remain increased for those individuals with elevated plasma ␤42 over nearly 10 years.
Mutations in the genes that cause early-onset, familial forms of AD increase the extracellular concentration of A␤42, which may augment A␤ deposition in the form of plaques in the brain. 35 This has led to the hypothesis that cerebral A␤ deposition is an essential early event in the pathogenesis of all forms of AD. Support for this hypothesis has come from the observation that plasma A␤40 and A␤42 levels were found to be higher in family members with mutations in presenilin 1 and the APP than among family members without the mutation. 8 We previously reported that plasma A␤42, but not A␤40, levels were increased among patients with incipient AD regardless of their APOE genotype in a small study from this same community. 6 Though patients with Down syndrome have higher plasma A␤40 and A␤42 levels due to the trisomy involving the region containing the APP, 36 even higher levels are found among pa- Comparisons are between participants who were alive or dead at the final assessment. Log-transformed values also differed significantly. Values in parentheses are SD. *Status refers to the vital status at final assessment. †Both nondemented elderly and patients with AD who died were significantly older than those surviving. ‡P Ͻ 0.001, comparing nondemented elderly follow-up alive vs dead. §P Ͻ 0.01, comparing AD follow-up alive vs dead.
A␤ ϭ amyloid ␤-peptide; AD ϭ Alzheimer's disease.
tients who became demented. 12, 37 It is not clear whether the APOE genotype influences plasma A␤40 and A␤42, because there are opposing reports. 12, 37 A␤40 and A␤42 levels in plasma represent a heritable trait 9 that has been used as a phenotype in a genetic linkage analysis 10 that showed genetic linkage to markers on chromosome 10. Do plasma A␤42 levels represent a potential biological risk factor for AD? Our study has indicated that the answer to this question is complex. First, plasma A␤40 and A␤42 levels show some degree of overlap between elderly individuals who eventually develop AD and those who remained healthy, as would be expected with any risk factor. Second, we demonstrated that the measurement of plasma A␤42 levels would need to be done at a point well before the onset of disease and thus could be used in the detection of individuals at higher-than-average risk. Careful inspection of the figure suggests that differences in frequency of AD by plasma A␤42 levels emerge only after 2 to 3 years of follow-up. Therefore, a cross-sectional comparison of patients with established diagnoses of AD and control subjects would be unlikely to show a difference in the mean levels of either peptide. Third, the validity of plasma A␤42 levels as a risk factor will be difficult to establish without more extensive longitudinal data because the highest levels were observed among individuals in the earliest stages of disease when the specificity of diagnosis is low. Therefore, high-risk individuals will need follow-up to a point at which the diagnostic specificity is greater. Although we observed little difference in the levels over a 3-year period, it may be necessary to complete repeated testing over a longer interval to examine changes in plasma levels with regard to disease course. Fourth, the highest A␤40 and A␤42 were found in those patients who died during the follow-up period, again implying that longitudinal, not cross-sectional, studies will be required to determine their usefulness in assessing disease risk. An alternative explanation is that the association with mortality implicates plasma A␤40 and A␤42 levels as indicators of prognosis.
We believe that neither plasma A␤40 nor A␤42 levels will be useful in the diagnosis of AD. Our limited results with repeated samples indicate that the plasma levels of A␤42 begin to decrease soon after the diagnosis of AD has been established, which has been observed by others. 38 Exactly when plasma levels begin to decrease is uncertain. In contrast, CSF concentrations of A␤42 have been used successfully when combined with other biochemical markers such as in the diagnosis of probable AD. 39, 40 A␤42 in the CSF is lower in patients with the disease than in controls. CSF concentrations of A␤42 are increased early in the disease and decrease over time. 41 Previous studies examining the role of plasma A␤40 and A␤42 levels have shown little or no value in the diagnosis of AD. 5, 42 We found an inverse relation between A␤40 levels and cholesterol and HDL in plasma. There may well be a relationship between A␤ deposition in brain and cholesterol, but it has not been observed in plasma. 43, 44 We could not identify an association between increased plasma A␤ and elevated serum cholesterol. 45 The studies of families with early-onset AD caused by mutations and the recent linkage of families with late-onset disease to chromosome 10 implicate exceptionally high plasma A␤42 levels as part of the phenotype of a form of familial AD. Thus, an alternative possibility is that plasma A␤42 may be increased only in a subset of individuals who develop AD. If the elevation in A␤42 is a phenotypic marker in some, but not all, patients, then the search for the genes associated with higher levels will be extremely important because new metabolic pathways may be revealed. The persistence of the elevation in the patients studied here, the sparse number of individuals with elevated levels, and their death over the follow-up would suggest a moderately aggressive form of the disease that can be either genetic or environmental.
Aside from studies of early-onset familial AD, 46,47 there have been no reports suggesting that elevated levels of circulating plasma A␤40 or A␤42 are associated with mortality. It is intriguing to speculate that in some individuals with AD, higher levels of A␤40 and A␤42 may reflect a more advanced stage of disease or a more aggressive form of AD. The only animal model that has been studied is the senescenceaccelerated mouse, which has a short life span and shows early signs of aging. 48 However, the amyloid deposition is systemic, affecting numerous systems in the body.
The source of A␤40 and A␤42 in plasma is unknown. A␤ is derived from proteolytic cleavage of the APP. 1 APP is produced by a variety of cell types in the brain and elsewhere, but the origins of A␤ brain deposits in AD and deposits in the cerebral vessels are uncertain. Amyloid deposits in cerebral vessels may be derived from circulating A␤. 49 Some have suggested that the source of parenchymal cerebral amyloid deposits may originate in the periphery. 50 Platelets contain high levels of membrane-associated and soluble forms of APP, which, when cleaved, can release A␤. [51] [52] [53] Platelets may also be the source of A␤ detected in whole blood 54 because A␤, like APP, is also released upon platelet activation. 52, 55 A␤ and APP formation and subsequent release from human platelets may be regulated by different multiple signal transduction mechanisms. 11 Knowledge of these mechanisms could provide a key to the pathogenesis of AD.
